BMO Capital analyst Gary Nachman kept his Outperform rating and $14 price target on scPharmaceuticals after its Q2 results, saying the investors’ focus remains on the company working through the FDA complete response letter for its Furoscix drug. The analyst notes that the management intends to address the issues raised by the FDA with its September 24th update, adding that after a 1-2 year delay, he still expects the drug to reach the market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.